Merck (MRK.US) stock jumped over 9% during today's session after drugmaker announced its new antiviral drug molnupiravir lower the risk of death or hospitalization by 50% for Covid patients. Experts say antiviral pills could be the last tool needed to beat back Covid-19.
Only 7.3% of patients who took the pill were hospitalized according to Phase 3 study results and none of them died. Meanwhile 14.1% of placebo recipients had to be hospitalized. Eight patients in the placebo group died. The pharmaceutical company plans to file for emergency use authorization. Today's news negatively affected other pharma-giants stocks. Pfizer-partner BioNTech (BNTX.US) and Novavax (NVAX.US) at one point fell 13% and 18%, respectively.
Merck (MRK.US) stock launched today's session sharply higher and broke above the lower limit of the triangle formation. Currently price is testing major resistance at $83.80 which is marked with upper limit of the 1:1 structure and 78.6% Fibonacci retracement of the last downward wave. Should a break higher occur, then the upward move may accelerate towards resistance at $ 88.27. However, if sellers will manage to halt advances here, then another downward impulse towards support at $78.35 may be launched. Source: xStation5
The AI front is burning. Samsung close to a breakthrough in the memory war!
US Open: Big Tech, Fed and Politics in Action. A Test Week Ahead for the Markets!
Mercosur: Farmers’ fears are exaggerated, industry triumphs - facts vs. myths
An Interesting Case of Nvidia in China. The Chip Paradox of the Year?
